Supernus Pharmaceuticals, Inc.
SUPNSupernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing central nervous system (CNS) therapies. Founded in 2005 and headquartered in Durham, North Carolina, the company specializes in treatments for conditions such as epilepsy, migraine, and psychiatric disorders. Supernus is known for its focus on formulations that improve patient adherence and quality of life.
Company News
Supernus Pharmaceuticals announced that President and CEO Jack A. Khattar will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. The company reported strong Q1 2026 financial results with total revenues of $207.7 million, representing a 39% increase year-over-year, with combined revenues from four ...
Supernus Pharmaceuticals announced that management will participate in three major healthcare investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference (March 2), Jefferies Biotech on the Beach Summit (March 10), and Barclays 28th Annual Global Healthcare Conference (March 11). Live webcasts will be available for select pres...
Aristotle Capital Boston reduced its holdings in Pharmaceuticals by 503,122 shares in Q3, decreasing its position value by approximately $10.9 million. Despite a 31% stock price increase over the past year, the company remains below its 2018 highs.
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.
